Procter & Gamble Health Reports 3% Sales Increase in Q2 2025
Filing Summary
Procter & Gamble Health Ltd. announced its unaudited financial results for the quarter ending September 30, 2025. The company reported a 3% increase in sales, reaching ₹319 crores, compared to the same period last year. Profit After Tax (PAT) rose by 8% to ₹89 crores. The growth was attributed to strong brand fundamentals and consumer response to new products. The results were approved by the Board of Directors on November 5, 2025. The company continues to focus on strategic efforts across its value chain.
Procter & Gamble Health Ltd. (PGHL) released its unaudited financial results for the second quarter ending September 30, 2025. The company reported sales of ₹319 crores, marking a 3% increase from the previous year. The Profit After Tax (PAT) for the quarter stood at ₹89 crores, reflecting an 8% growth compared to the same period last year.
The financial results were approved at a meeting of the Board of Directors held on November 5, 2025. The company attributed the sales growth to strong brand fundamentals and a positive consumer response to new innovations. The increase in PAT was driven by the growth in sales.
Procter & Gamble Health highlighted strategic efforts across its value chain, including consumer communication initiatives and the introduction of new products such as Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream. The company also emphasized its focus on strengthening supply chain capabilities to meet the evolving needs of consumers, customers, and healthcare professionals.
Procter & Gamble Health Ltd. is a leading company in India’s vitamins, minerals, and supplements sector. It manufactures and markets products aimed at promoting a healthy lifestyle and improved quality of life. The company’s product portfolio includes well-known brands such as Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion.